Srihari Vedartham

Srihari Vedartham has more than 15 years of experience with profit and loss responsibility for the business development and product development efforts; a deal sheet of more than10 transactions (>$700 million) and raising more than $100 million of financing through deal making and new product planning efforts. He has successful specialty drug launch experience, including Atryn, Xenazine, Sabril, and Onfi. He has demonstrated expertise and success in starting companies from the ground up. His experience includes working in organizations with fewer than 20 employees and more than 6,000 employees worldwide.

Srihari holds a Master’s degree in Organic Chemistry from Osmania University in India and an MBA from Tennessee Tech University.